Interestingly, combining an anti-mouse PD-1 antibody and the p110β isoform-specific inhibitor GSK2636771 significantly reduced tumor growth and survival relative to monotherapy in Braf-mutant, Pten-null melanoma in vivo, and was associated with increased T-cell infiltration [369]. Here, BRAF is linked to melanoma.